Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pexelizumab, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lerdelimumab, an antibody targeting TGFB1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zanolimumab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Naptumomab, an antibody targeting TPBG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Efungumab, an antibody targeting Heat Shock Protein 90 Homolog.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abagovomab, an antibody targeting MUC16.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tanezumab, an antibody targeting NGFB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Farletuzumab, an antibody targeting Folate receptor alpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Girentuximab, an antibody targeting CA9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Clivatuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Onartuzumab, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ganitumab, an antibody targeting IGF-1R.